Cited by 339Bone Metabolism and DiseasesBone health and osteoporosis researchOsteomyelitis and Bone Disorders Research

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

The RANKL/RANK/OPG pathway

Boyce, Brendan F., Xing, Lianping·2007·Current Osteoporosis Reports

DOI 10.1007/s11914-007-0024-y

Open this paper in CoChat — free account

Abstract

Understanding of osteoclast formation and activation has advanced considerably since the discovery of the RANKL/RANK/OPG system in the mid 1990s. Osteoblasts and stromal stem cells express receptor activator of NF-jB ligand (RANKL), which binds to its receptor, RANK, on the surface of osteoclasts and their precursors. This regulates the differentiation of precursors into multinucleated osteoclasts and osteoclast activation and survival both normally and in most pathologic conditions associated with increased bone resorption. Osteoprotegerin (OPG) is secreted by osteoblasts and osteogenic stromal stem cells and protects the skeleton from excessive bone resorption by binding to RANKL and preventing it from interacting with RANK. The RANKL/OPG ratio in bone marrow is thus an important determinant of bone mass in normal and disease states. RANKL/RANK signaling also regulates lymph node formation and mammary gland lactational hyperplasia in mice, and OPG protects large arteries of mice from medial calcification. This article reviews the roles of the RANKL/RANK/OPG system in bone and other tissues.

Integrity signals

Registry

Crossref · 10.1007/s11914-007-0024-y

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de Crombrugghe, B. (2002) · Cell · doi:10.1016/s0092-8674(01)00622-5 · Cited by 3,608
Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
Genetic regulation of osteoclast development and function
Teitelbaum, S. L., & Ross, F. P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1122 · Cited by 1,720
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signalingPreprint
Lomaga, M. A., Yeh, W., Sarosi, I., Duncan, G. S., Furlonger, C. L., Ho, A. P., Morony, S., Capparelli, C., Van, G. Y., Kaufman, S., et al. (1999) · Genes & Development · doi:10.1101/gad.13.8.1015 · Cited by 1,265
RANKL–RANK signaling in osteoclastogenesis and bone disease
Wada, T., Nakashima, T., Nishina, H., & Penninger, J. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.11.007 · Cited by 1,230
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro1
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J., Lang, T., Garnero, P., Bouxsein, M., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,168
TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells
Wong, B. R., Rho, J., Arron, J. R., Robinson, E. A., Orlinick, J. R., Chao, M. V., Kalachikov, S. M., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 990
Role of osteoblasts in hormonal control of bone resorption—A hypothesis
Rodan, G. A., & Martin, T. J. (1981) · Calcified Tissue International · doi:10.1007/bf02409454 · Cited by 982
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis
Asagiri, M., Sato, K., Usami, T., Ochi, S., Nishina, H., Yoshida, H., Morita, I., Wagner, E. F., Mak, T. W., Serfling, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051150 · Cited by 849
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis
Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., Iwata, T., Ohnishi, H., Matozaki, T., Kodama, T., et al. (2004) · Nature · doi:10.1038/nature02444 · Cited by 832
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells
Kollet, Ó., Dar, A., Shivtiel, S., Kalinkovich, A., Lapid, K., Sztainberg, Y., Tesio, M., Samstein, R. M., Goichberg, P., Spiegel, A., et al. (2006) · Nature Medicine · doi:10.1038/nm1417 · Cited by 774
The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development.
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β
Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H. I., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., et al. (2002) · Nature · doi:10.1038/416744a · Cited by 719
Osteoclast-derived activity in the coupling of bone formation to resorption
Martin, T. J., & Sims, N. A. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.004 · Cited by 661
Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice
Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, K., Nakamura, K., Katsuki, M., Yamamoto, T. S., et al. (1999) · Genes to Cells · doi:10.1046/j.1365-2443.1999.00265.x · Cited by 626
TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases
Feldmann, M., & Maini, R. N. (2003) · Nature Medicine · doi:10.1038/nm939 · Cited by 586
v-ATPase V0 subunit d2–deficient mice exhibit impaired osteoclast fusion and increased bone formation
Lee, S.-H., Rho, J., Jeong, D., Sul, J., Kim, T. S., Kim, N., Kang, J.-S., Miyamoto, T. K., Suda, T., Lee, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1514 · Cited by 547
NFAT and Osterix cooperatively regulate bone formation
Koga, T., Matsui, Y., Asagiri, M., Kodama, T., Crombrugghe, B. D., Nakashima, K., & Takayanagi, H. (2005) · Nature Medicine · doi:10.1038/nm1270 · Cited by 497
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
Hughes, A. E., Ralston, S. H., Marken, J., Bell, C., Macpherson, H. K., Wallace, R. G. H., Hul, W. V., Whyte, M. P., Nakatsuka, K., Hovy, L., et al. (2000) · Nature Genetics · doi:10.1038/71667 · Cited by 484
Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Collin‐Osdoby, P. (2004) · Circulation Research · doi:10.1161/01.res.0000149165.99974.12 · Cited by 474
Osteoprotegerin Deficiency and Juvenile Paget's Disease
Whyte, M. P., Obrecht, S. E., Finnegan, P. M., Jones, J. L., Podgornik, M. N., McAlister, W. H., & Mumm, S. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013096 · Cited by 446
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., Vargo-Gogola, T. C., Begtrup, J. L., Peterson, T. E., Fingleton, B., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.013 · Cited by 402
Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE −/− Mice
Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000236428.91125.e6 · Cited by 304 · cited 1×
“Although this observation suggests that OPG may protect against calcification of atherosclerosis [ 36 ], it remains to be determined whether OPG or RANKL signaling play important roles in cardiovascular disease.”
Background
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
Chen, G., Sircar, K., Aprikian, A. G., Potti, A., Goltzman, D., & Rabbani, S. A. (2006) · Cancer · doi:10.1002/cncr.21978 · Cited by 229
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype
Cundy, T. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.18.2119 · Cited by 228
Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus*
Ikeda, T., Kasai, M., Utsuyama, M., & Hirokawa, K. (2001) · Endocrinology · doi:10.1210/endo.142.4.8070 · Cited by 215
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α–transgenic mice
Li, P., Schwarz, E. M., O’Keefe, R. J., Ma, L., Looney, R. J., Ritchlin, C. T., Boyce, B. F., & Xing, L. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11419 · Cited by 208
Self-citation
Tumor Necrosis Factor-α Increases Circulating Osteoclast Precursor Numbers by Promoting Their Proliferation and Differentiation in the Bone Marrow through Up-regulation of c-Fms Expression
Yao, Z., Li, P., Zhang, Q., Schwarz, E. M., Keng, P., Arbini, A., Boyce, B. F., & Xing, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512624200 · Cited by 197
Self-citation
Mechanisms of Disease: the link between RANKL and arthritic bone disease
Schett, G. A., Hayer, S., Zwerina, J., Redlich, K., & Smolen, J. S. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0036 · Cited by 189
Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation
ÉBAUD, D. T., Krieg, M., Berguer, D. G., Jacquet, A. F., Goy, J., & BURCKHARDT, P. (1996) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1996.00170.x · Cited by 154
Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease
Kurihara, N., Hiruma, Y., Zhou, H., Subler, M. A., Dempster, D. W., Singer, F. R., Reddy, S. V., Gruber, H. E., Windle, J. J., & Roodman, G. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28267 · Cited by 127
Receptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2
Kim, N., Kim, H.-J., Koo, B., Kwon, M.-C., Kim, Y.-W., Cho, Y., Yokota, Y., Penninger, J. M., & Kong, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1002-1013.2006 · Cited by 110
New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1–34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats
Ma, Y. L., Bryant, H. U., Zeng, Q., Schmidt, A., Hoover, J. L., Cole, H. W., Yao, W., Jee, W. S. S., & Sato, M. (2003) · Endocrinology · doi:10.1210/en.2002-221061 · Cited by 91
Embryonic Heart Failure in NFATc1 −/− Mice
Phoon, C. K. L., Ji, R. P., Aristizábal, O., Worrad, D. M., Zhou, B., Baldwin, H. S., & Turnbull, D. H. (2004) · Circulation Research · doi:10.1161/01.res.0000133681.99617.28 · Cited by 91
Osteoprotegerin, the bone protector, is a surprising target for β-catenin signaling
Boyce, B. F., Xing, L., & Chen, D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.11.011 · Cited by 54
Self-citation
Malignant Autosomal Recessive Osteopetrosis Caused by Spontaneous Mutation of Murine Rank
Kapur, R. P., Yao, Z., Iida, M. H., Clarke, C. M., Doggett, B., Xing, L., & Boyce, B. F. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040713 · Cited by 39
Self-citation

Research works printed but not linked: 2

American Society for Bone and Mineral Research President’s Committee on Nomenclature: Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President’s Committee on Nomenclature. J Bone Miner Res 2000, 15:2293–2296.
Yao Z, Matsuo K, Nishimura R, et al.: c-Fos/NFAT1-or 2-mediated osteoclastogenesis requires NF-κB p50/p52 expression [abstract]. J Bone Miner Res 2005, 20(suppl 1):S145.

Sorted by citations

Coupling of bone resorption and formation by RANKL reverse signalling
Ikebuchi, Y., Aoki, S., Honma, M., Hayashi, M., Sugamori, Y., Khan, M., Kariya, Y., Kato, G., Tabata, Y., Penninger, J. M., et al. (2018) · Nature · doi:10.1038/s41586-018-0482-7 · Cited by 557
RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling
Tobeiha, M., Moghadasian, M. H., Amin, N., & Jafarnejad, S. (2020) · BioMed Research International · doi:10.1155/2020/6910312 · Cited by 309
Osteoporosis in Inflammatory Bowel Disease
Ali, T., Lam, D. W.-H., Bronze, M. S., & Humphrey, M. B. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.022 · Cited by 277
Cancer-Related Hypercalcemia
Goldner, W. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011155 · Cited by 241
Role of osteopontin in bone remodeling and orthodontic tooth movement: a review
Singh, A., Gill, G., Kaur, H., Amhmed, M., & Jakhu, H. (2018) · Progress in Orthodontics · doi:10.1186/s40510-018-0216-2 · Cited by 229

See all 339

Authors: Boyce, B. F., & Xing, L.
Affiliations: University of Rochester Medicine (US)
Corresponding author: Boyce, Brendan F.
ORCID: Boyce, Brendan F.
Xing, Lianping
Venue: Current Osteoporosis Reports
Publisher: Springer Science and Business Media LLC
Published: 2007-09
Volume: 5
Issue: 3
Pages: 98-104
ISSN: 1544-1873 (ISSN-L)
1544-2241
DOI: 10.1007/s11914-007-0024-y
OpenAlex: W2055590859
Cited by: 339
References: 48
Citations by year: 2026: 18 · 2025: 22 · 2024: 32 · 2023: 29 · 2022: 30 · 2021: 26 · 2020: 31 · 2019: 21 · 2018: 24 · 2017: 25 · 2016: 20 · 2015: 17 · 2014: 4 · 2013: 8 · 2012: 5
FWCI: 2.65
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Current Osteoporosis Reports (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
Keywords: RANK/RANKL/OPG pathway, osteoclastogenesis, osteoclast activation, bone resorption, osteoblasts, stromal stem cells, RANKL/OPG ratio, bone mass regulation, vascular calcification, NF-κB signaling
MeSH terms: Humans, Osteoclasts, Osteoporosis, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The RANKL/RANK/OPG pathway

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks